Can the Sareum share price keep climbing?

The Sareum share price has surged more than 360% in 12 months. Can it continue climbing? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

CORRECTION: The original version of this article incorrectly stated that Sareum was trading at 170p.

The Sareum (LSE:SAR) share price has been growing rapidly recently. Over the last 12 months, it’s increased from 0.37p all the way to 1.70p at the time of writing. That’s almost a 360% rise in a relatively short space of time. What caused this enormous growth? And should I be adding the stock to my portfolio? Let’s take a look.

Sareum’s rising share price

Sareum is a biotech company specialising in discovering new treatments for cancer and autoimmune diseases. The business generates income by licensing its drug candidates to pharmaceutical companies. Under these agreements, the licensee funds the remainder of development. In exchange, it gains complete commercial control if the drug reaches the market. Meanwhile, Sareum receives payments for each milestone achieved and eventually receives royalties on future drug sales.

The firm currently has seven treatments in its pipeline. And in 2020, some significant progress was made that caused the Sareum share price to start rising. Both of its proprietary treatments for cancer and autoimmune diseases named SDC-1801 and SDC-1802 showed positive pre-clinical results. And so, the company has begun preparations for human trials starting as early as Q1 2021.

It also signed a new licensing deal with a China-based pharmaceutical company for its FLT+3 Aurora programme. And on top of all that, its Chk1 project – licensed to Sierra Oncology – successfully completed its phase I/II trials. This is particularly exciting as under the licensing agreement with Sierra, Sareum is eligible to receive 27.5% of all sales as royalties.

There are risks to be considered

The progress made in 2020 is undoubtedly fantastic news for Sareum and its share price. However, there are some significant risks ahead.

Drug development is a long and expensive process, and incredibly challenging. The regulatory requirements alone often lead to 90% of drug failing during phase I trials. Needless to say, the odds are stacked against SDC-1801 and SDC-1802. Even if they eventually gain regulatory approval, it could be several years before Sareum has any licensed products on the market.

It takes an average of 10 years to commercialise a new treatment. And while the company has several drugs entering the last stage of development, phase III is by far the longest, often lasting several years of clinical trials.

The Sareum share price might be too high

The bottom line

As promising as Sareum’s preliminary results are, the company is a long way off from generating any significant revenue. And so, its share price appears to be driven primarily by shareholder expectations. But providing that the firm can keep producing positive results, I believe its share price will continue to climb higher.

Having said that, I personally believe it’s too soon to invest. The risk of a drug failing in the early stages of development is incredibly high and could lead to significant short-term volatility. Therefore I won’t be adding Sareum to my portfolio today. But I will be keeping a close eye on how it performs over the next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Sareum. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 recession-resistant UK stocks I’d buy and hold for a decade!

Our writer details two UK stocks she believes could still continue to perform well in a recession and not feel…

Read more »

Back view of blue NIO EP9 electric vehicle
Investing Articles

Down 31% this year! Is now the moment to buy NIO stock?

NIO stock has moved sharply downwards in the past couple of months. Christopher Ruane likes the business potential -- but…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 dividend stocks I reckon could grow payouts for years to come!

This Fool is looking for dividend stocks and explains why these two picks could be primed to grow their payouts…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Should I buy, sell, or hold my Rolls-Royce shares at £3.50?

This Fool considers what he should do with his Rolls-Royce shares following the FTSE 100 company's excellent full-year results last…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

With a spare £280, here’s how I’d start buying shares this March

Our writer reflects on what he has learnt on the stock market to explain how he would start buying shares…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Are these expensive FTSE 100 stocks actually brilliant bargains?

Paul Summers takes a closer look at two FTSE 100 stocks that could recover strongly in time, despite already carrying…

Read more »

Investing Articles

What might the recent Aviva share price performance tell me as an investor?

Christopher Ruane looks at how the Aviva share price has performed over the past 12 months and considers whether he…

Read more »

Investing Articles

Down by a quarter, is the BT share price a steal?

The BT share price has more than halved in the past five years. What is holding it down -- and…

Read more »